T1	PROC 45 98	ESTUDIO DE INDUCCIÓN SOBRE LA EFICACIA Y LA SEGURIDAD
T2	DISO 117 133	COLITIS ULCEROSA
#1	AnnotatorNotes T2	C0009324; Ulcerative Colitis; Disease or Syndrome
T3	PROC 154 274	Estudio de inducción en fase III, multicéntrico, aleatorizado, doble ciego, de grupos paralelos y controlado con placebo
T4	DISO 911 923	intolerancia
#2	AnnotatorNotes T4	C0277585; Intolerance to drug; Pathologic Function
T5	DISO 347 363	colitis ulcerosa
#3	AnnotatorNotes T5	C0009324; Ulcerative Colitis; Disease or Syndrome
T6	DISO 412 428	Colitis Ulcerosa
#4	AnnotatorNotes T6	C0009324; Ulcerative Colitis; Disease or Syndrome
T7	PROC 631 642	Diagnóstico
#5	AnnotatorNotes T7	C0011900; Diagnosis; Diagnostic Procedure
T8	DISO 646 648	CU
#6	AnnotatorNotes T8	C0009324; Ulcerative Colitis; Disease or Syndrome
T9	PROC 700 711	Diagnóstico
#7	AnnotatorNotes T9	C0011900; Diagnosis; Diagnostic Procedure
T10	CHEM 1472 1484	risankizumab
#8	AnnotatorNotes T10	C4505511; risankizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T11	DISO 726 728	CU
#9	AnnotatorNotes T11	C0009324; Ulcerative Colitis; Disease or Syndrome
T12	PROC 766 776	evaluación
#10	AnnotatorNotes T12	C1261322; Evaluation procedure; Health Care Activity
T13	PROC 927 963	tratamiento convencional o biológico
T14	DISO 972 974	CU
#11	AnnotatorNotes T14	C0009324; Ulcerative Colitis; Disease or Syndrome
T15	PROC 1023 1046	métodos anticonceptivos
#12	AnnotatorNotes T15	C0700589; Contraceptive methods; Therapeutic or Preventive Procedure
T16	PROC 1149 1160	diagnóstico
#13	AnnotatorNotes T16	C0011900; Diagnosis; Diagnostic Procedure
T17	DISO 1171 1190	enfermedad de Crohn
#14	AnnotatorNotes T17	C0010346; Crohn Disease; Disease or Syndrome
T18	DISO 1193 1242	enfermedad inflamatoria intestinal no clasificada
#15	AnnotatorNotes T18	C4268603; Colonic inflammatory bowel disease unclassified; Disease or Syndrome
T19	DISO 1244 1265	colitis indeterminada
#16	AnnotatorNotes T19	C0941062; Unspecified colitis; Disease or Syndrome
T20	PROC 1285 1295	colectomía
#17	AnnotatorNotes T20	C0009274; Colectomy; Therapeutic or Preventive Procedure
T21	DISO 1342 1358	megacolon tóxico
#18	AnnotatorNotes T21	C0025162; Megacolon, Toxic; Disease or Syndrome
T22	CHEM 1388 1412	anticuerpos anti-IL12p40
T23	CHEM 1422 1433	ustekinumab
#19	AnnotatorNotes T23	C1608841; ustekinumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T24	CHEM 1437 1462	anticuerpos anti-IL-23p19
T25	CHEM 1486 1496	brazikumab
T26	CHEM 1498 1508	guselkumab
#20	AnnotatorNotes T26	C3852217; guselkumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T27	CHEM 1511 1524	tildrakizumab
#21	AnnotatorNotes T27	C4043954; tildrakizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T28	ANAT 1217 1227	intestinal
#22	AnnotatorNotes T28	C0021853; Intestines; Body Part, Organ, or Organ Component | C1318303; Entire intestine; Body Part, Organ, or Organ Component
T29	CHEM 102 113	MIRIKIZUMAB
#23	AnnotatorNotes T29	C5139904; Mirikizumab; Immunologic Factor; Amino Acid, Peptide, or Protein; Pharmacologic Substance
T30	CHEM 281 292	mirikizumab
#24	AnnotatorNotes T30	C5139904; mirikizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T31	Date 13 17	2017
T32	LIVB 296 305	pacientes
#25	AnnotatorNotes T32	C0030705; Patients; Patient or Disabled Group
T33	LIVB 516 533	Pacientes hombres
#26	AnnotatorNotes T33	C0030705; Patients; Patient or Disabled Group + C0025266; Male population group; Population Group
T35	LIVB 536 543	mujeres
#27	AnnotatorNotes T35	C0043210; Woman; Population Group
T36	Age 569 589	entre ≥18 y ≤80 años
T37	Duration 657 677	al menos los 3 meses
T40	LIVB 985 990	mujer
#28	AnnotatorNotes T40	C0043210; Woman; Population Group
T41	LIVB 1135 1144	Pacientes
#29	AnnotatorNotes T41	C0030705; Patients; Patient or Disabled Group
T42	Date 1161 1167	actual
T44	LIVB 1271 1280	Pacientes
#30	AnnotatorNotes T44	C0030705; Patients; Patient or Disabled Group
T45	LIVB 1307 1316	Pacientes
#31	AnnotatorNotes T45	C0030705; Patients; Patient or Disabled Group
T46	Spec_cue 1321 1329	indicios
T47	Date 1330 1338	actuales
A1	Assertion T21 Speculated
A2	Status T20 History_of
A3	Status T22 History_of
A4	Status T23 History_of
A5	Status T24 History_of
A6	Status T10 History_of
A7	Status T25 History_of
A8	Status T26 History_of
A9	Status T27 History_of
#32	AnnotatorNotes T25	C5238125; Brazikumab; Amino Acid, Peptide, or Protein · Pharmacologic Substance · Immunologic Factor 
#33	AnnotatorNotes T42	C0521116; Current (present time); Temporal Concept 
#34	AnnotatorNotes T47	C0521116; Current (present time); Temporal Concept 
T34	Quantifier_or_Qualifier 1231 1242	clasificada
A10	Assertion T34 Negated
#35	AnnotatorNotes T34	C0008902; Classification; Classification
T38	Neg_cue 1228 1230	no
T39	Observation 887 907	pérdida de respuesta
#36	AnnotatorNotes T39	C5400193; Loss of therapeutic response; Finding
T43	Observation 865 885	respuesta inadecuada
R1	Experiences Arg1:T32 Arg2:T30	
T48	Quantifier_or_Qualifier 364 370	activa
#37	AnnotatorNotes T48	C0679217; Active State; Idea or Concept
R2	Has_Quantifier_or_Qualifier Arg1:T5 Arg2:T48	
T49	Quantifier_or_Qualifier 729 735	activa
#38	AnnotatorNotes T49	C0679217; Active State; Idea or Concept
R3	Has_Quantifier_or_Qualifier Arg1:T11 Arg2:T49	
T50	Quantifier_or_Qualifier 374 390	moderada a grave
#39	AnnotatorNotes T50	C1299393; Moderate to severe; Qualitative Concept
R4	Has_Quantifier_or_Qualifier Arg1:T5 Arg2:T50	
T51	Quantifier_or_Qualifier 739 755	moderada a grave
#40	AnnotatorNotes T51	C1299393; Moderate to severe; Qualitative Concept
R5	Has_Quantifier_or_Qualifier Arg1:T11 Arg2:T51	
R6	Experiences Arg1:T32 Arg2:T5	
R7	Has_Age Arg1:T35 Arg2:T36	
R8	Has_Age Arg1:T33 Arg2:T36	
T52	PROC 610 619	selección
#41	AnnotatorNotes T52	C0242802; Patient Selection; Research Activity
R9	Overlap Arg1:T52 Arg2:T36	
R10	Has_Duration_or_Interval Arg1:T8 Arg2:T37	
T53	CONC 689 695	inicio
#42	AnnotatorNotes T53	C0439659; Beginning; Temporal Concept
R11	Before Arg1:T8 Arg2:T53	
R12	Before Arg1:T7 Arg2:T53	
T54	CONC 783 812	puntuación de Mayo modificada
R13	Used_for Arg1:T54 Arg2:T12	
R14	Before Arg1:T12 Arg2:T9	
R15	Causes Arg1:T13 Arg2:T4	
R16	Overlap Arg1:T39 Arg2:T13	
R17	Overlap Arg1:T43 Arg2:T13	
R18	Experiences Arg1:T40 Arg2:T15	
T55	Observation 310 342	fracaso convencional y biológico
R19	Experiences Arg1:T32 Arg2:T55	
R20	Before Arg1:T55 Arg2:T30	
R21	Before Arg1:T5 Arg2:T55	
R23	Experiences Arg1:T41 Arg2:T17	
R24	Overlap Arg1:T16 Arg2:T42	
R25	Experiences Arg1:T41 Arg2:T18	
R26	Negation Arg1:T38 Arg2:T34	
R27	Location_of Arg1:T28 Arg2:T18	
R28	Experiences Arg1:T41 Arg2:T19	
R29	Experiences Arg1:T44 Arg2:T20	
R30	Speculation Arg1:T46 Arg2:T21	
R31	Overlap Arg1:T21 Arg2:T47	
R32	Experiences Arg1:T45 Arg2:T21	
#43	AnnotatorNotes T43	C0858218; Inappropriate drug response; Finding
#44	AnnotatorNotes T13	C2945704; Conventional Treatment; Therapeutic or Preventive Procedure + C1531518; Biological treatment; Therapeutic or Preventive Procedure
A11	Experiencer T32 Patient
A12	Experiencer T33 Patient
A13	Experiencer T35 Patient
A14	Experiencer T40 Patient
A15	Assertion T40 Hypothetical
A16	Experiencer T41 Patient
A17	Experiencer T44 Patient
A18	Experiencer T45 Patient
